Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats.

  title={Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats.},
  author={Daniel P Bradley and Jean J L Tessier and Susan Elizabeth Ashton and John C. Waterton and Zena Wilson and Philip L. Worthington and Anderson Joseph AstraZeneca R D Alderley Ryan},
  volume={9 5},
Magnetic resonance imaging (MRI) can measure the effects of therapies targeting the tumor vasculature and has demonstrated that vascular-damaging agents (VDA) induce acute vascular shutdown in tumors in human and animal models. However, at subtherapeutic doses, blood flow may recover before the induction of significant levels of necrosis. We present the relationship between changes in MRI biomarkers and tumor necrosis. Multiple MRI measurements were taken at 4.7 T in athymic rats (n = 24… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 15 extracted citations

Functional MRI and CT biomarkers in oncology

European Journal of Nuclear Medicine and Molecular Imaging • 2014
View 4 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 48 references

Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2003
View 6 Excerpts
Highly Influenced

Differentiation and definition of vascular-targeted therapies.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2005

Diffusionweighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin A-4 phosphate after repeated administration. Neoplasia 7, 779–787

HC Thoeny, F De Keyzer, +7 authors R Hermans
MRI Measurement of Tumor Necrosis Bradley et al. 391 Neoplasia • 2005

Similar Papers

Loading similar papers…